- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Biogen Idec Inc (BIIB)
| Open: | 132.2500 | Day's Range: | 131.0700 - 132.8990 | Volume: | 757,174 | Bid: | 131.5600 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 131.6500 | 52wk Range: | 83.8300 - 138.4950 | 1-Yr Rtn: | +41.14% | Ask: | 131.5700 |
Stock Chart for BIIB
Key Statistics for BIIB
| Current P/E Ratio (ttm) | 25.3487 |
|---|---|
| Estimated P/E (12/2012) | 21.2023 |
| Earnings Per Share (USD) (ttm) | 5.1900 |
| Est. EPS (USD) (12/2012) | 6.2050 |
| Est. PEG Ratio | 1.4260 |
| Market Cap (M USD) | 31,516.89 |
| Shares Outstanding (M) | 239.56 |
| Enterprise Value (M USD) (ttm) | 29,850.36 |
| Enterprise Value/EBITDA (ttm) | 14.44 |
| Price/Book (mrq) | 4.9980 |
| Price/Sale (ttm) | 6.1970 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/26/2012 |
More BIIB Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for BIIB
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for BIIB
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
| William D Young "Bill"Chairman | George A ScangosChief Executive Officer |
| Alfred W Sandrock JrChief Medical Officer | Paul J ClancyExec VP:Finance/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page